Gene therapy expression vectors based on the clotting Factor IX promoter

Gene Therapy

Volumn 6, Issue 9, 1999, Pages 1584-1589

  Hoag, H ^a   Gore, J ^a   Barry, D ^a   Mueller, C R ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Factor IX; Gene expression; Gene therapy; Liver; Tissue specific; Transcription

Indexed keywords

APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 9;

ARTICLE; BREAST CELL; CELL LINE; CONTROLLED STUDY; ENHANCER REGION; EXPRESSION VECTOR; GENE EXPRESSION; GENE STRUCTURE; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LIVER; LIVER CELL; MUSCLE CELL; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; SIMIAN VIRUS 40;

CELL LINE; FACTOR IX; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER; LUCIFERASES; PROMOTER REGIONS (GENETICS);

SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0032847744     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300985     Document Type: Article

References (25)

1. Sandig V, Strauss M. Liver-directed gene transfer and application to therapy. J Mol Med 1996; 74: 205-212.
2. Eisensmith RC, Woo SL. Viral vector-mediated gene therapy for hemophilia B. Thromb Haemostas 1997; 78: 24-30.
3. Snyder RO et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
4. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Therapy 1996; 3: 802-810.
5. Nakai H et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998; 91: 4600-1607.
6. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
7. Ponder KP et al. Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection. Hum Gene Ther 1991; 2: 41-52.
8. Hafenrichter DG et al. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 1994; 84: 3394-3404.
9. Okuyama T et al. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Hum Gene Ther 1996; 7: 637-645.
10. Reijnen MJ, Bertina RM, Reitsma PH. Localization of transcription initiation sites in the human coagulation factor IX gene. FEBS Lett 1990; 270: 207-210.
11. Picketts DJ, Lillicrap DP, Mueller CR. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Nat Genet 1993; 3: 175-179.
12. Thompson AR. Structure, function, and molecular defects of factor IX. Blood 1986; 67: 565-572.
13. Briet E, Bertina RM, van Tilburg NH, Veltkamp JJ. Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. New Engl J Med 1982; 306: 788-790.
14. Crossley M et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257: 377-379.
15. Boccia LM, Lillicrap D, Newcombe K, Mueller CR. Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation. Mol Cell Biol 1996; 16: 1929-1935.
16. Reijnen MJ et al. Hemophilia B Leyden: substitution of thymine for guanine at position-21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood 1993; 82: 151-158.
17. Drazan KE, Wu L, Bullington D, Shaked A. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg 1996; 31: 411-414.
18. Grosveld F et al. The dynamics of globin gene expression and gene therapy vectors. Ann NY Acad Sci 1998; 850: 18-27.
19. Allan CM, Taylor S, Taylor JM. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J Biol Chem 1997; 272: 29113-29119.
20. Allan CM, Walker D, Taylor JM. Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus. Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice. J Biol Chem 1995; 270: 26278-26281.
21. Picketts DJ, Mueller CR, Lillicrap D. Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood 1994; 84: 2992-3000.
22. Friedman AD, Landschulz WH, McKnight SL. C/EBP activates the promoter of the serum albumin gene in cultured hepatoma cells. Genes Dev 1989; 3: 1314-1322.
23. Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occuring regulatory sequences. Nat Biotechnol 1999; 17: 241-245.
24. Maire P, Wuarin J, Schibler U. The role of cis-acting elements in tissue-specific albumin gene transcription. Science 1989; 244: 343-346.
25. Picketts DJ, Mueller CR, Lillicrap DP. Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood 1994; 84: 2992-3000.